Topic List : Precision Health
Stanford's COVID-19 testing provided for Bay Area hospitals
Stanford’s test for COVID-19, caused by the novel coronavirus, is rapidly expanding capacity to serve patients in the Bay Area and beyond. Researchers hope to soon be able to process more than 1,000 tests per day.
Potential treatment for lingering Lyme disease
Screening thousands of drugs, Stanford scientists determined that in mice, azlocillin, an antibiotic approved by the Food and Drug Administration, eliminated the bacteria that causes Lyme disease.
Stanford-led teams nab top clinical research prizes
Winning studies were chosen by members of the Clinical Research Forum, a nonprofit foundation that promotes the understanding of clinical research and its impact on health and health care.
Brain waves can determine drug response
Researchers used electroencephalography and artificial intelligence to identify individuals who would likely respond to sertraline, the antidepressant marketed as Zoloft.
Single number IDs deadly cancer cells
Stanford data scientists have shown that figuring out a single number can help them find the most dangerous cancer cells.
‘Ageotypes’ show how we age
Stanford scientists have identified specific biological pathways along which individuals age over time.
Stanford Medicine unveils 2020 Health Trends Report
The report documents key trends steering the industry’s future, including a maturing digital health market, new health laws opening patient access to data, and artificial intelligence gaining regulatory traction for medical use.
New Stanford Hospital: The future is here
This issue contains stories behind the development of the new hospital as well as articles about the work being done there.
E.H.R. event tackles privacy, workload
Speakers at Stanford Medicine’s second symposium on electronic health records discussed ways to increase patients’ access to data while maintaining security and decreasing the documentation burden for physicians.
Cancer-drug combo extends life about 9 months
The results of a phase-3 clinical trial led by a Stanford researcher showed that two targeted treatments can extend the lifespan and delay the need for chemotherapy in women with a common type of metastatic breast cancer.